(Q37850376)

24 August 2017

1 reference

title

Ramipril. A review of its pharmacological properties and therapeutic efficacy in cardiovascular disorders (English)

1 reference

24 August 2017

1 reference

1 reference

P A Todd

1

1 reference

24 August 2017

P Benfield

series ordinal

2

1 reference

24 August 2017

publication date

1 January 1990

1 reference

24 August 2017

1 reference

24 August 2017

volume

39

1 reference

24 August 2017

issue

1

1 reference

24 August 2017

page(s)

110-135

1 reference

Effect of ramipril on 24-hour variability of blood pressure and heart rate in essential hypertension

24 August 2017

cites work

1 reference

12 December 2020

Lisinopril. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension and congestive heart failure

1 reference

12 December 2020

Inhibition of angiotensin converting enzyme: mechanism and substrate dependence

1 reference

12 December 2020

Reduction of reperfusion arrhythmias in the ischemic isolated rat heart by angiotensin converting enzyme inhibitors: a comparison of captopril, enalapril, and HOE 498

1 reference

12 December 2020

Persistent tissue converting enzyme inhibition following chronic treatment with Hoe498 and MK421 in spontaneously hypertensive rats

1 reference

12 December 2020

Ramipril for hypertension secondary to renal artery stenosis. Changes in blood pressure, the renin-angiotensin system and total and divided renal function

1 reference

12 December 2020

Ramipril and captopril in patients with heart failure: effects on hemodynamics and vasoconstrictor systems.

1 reference

12 December 2020

Clinical pharmacology of ramipril

1 reference

12 December 2020

The renin-angiotensin system in the control of systemic arterial pressure

1 reference

12 December 2020

Humoral and blood pressure effects of the angiotensin converting enzyme inhibitor ramipril in essential hypertension

1 reference

12 December 2020

Antihypertensive action of the converting enzyme inhibitor perindopril (S9490-3) in spontaneously hypertensive rats: comparison with enalapril (MK421) and ramipril (Hoe498).

1 reference

12 December 2020

The effect of the converting enzyme inhibitor HOE 498 on the renin angiotensin system of normal volunteers

1 reference

12 December 2020

Effect of ramipril, a new angiotensin converting enzyme inhibitor, on diurnal variations of blood pressure in essential hypertension

1 reference

12 December 2020

Beneficial effects of the converting enzyme inhibitor, ramipril, in ischemic rat hearts

1 reference

12 December 2020

Cardiovascular effects of the converting enzyme inhibitor ramipril (HOE 498) in anesthetized dogs with acute ischemic left ventricular failure.

1 reference

12 December 2020

Angiotensin II-Mediated Vasoconstriction in Chronic Congestive Heart Failure, and Response to Converting Enzyme Inhibition

1 reference

12 December 2020

Antihypertensive action and inhibition of tissue converting enzyme (CE) by three prodrug CE inhibitors, enalapril, ramipril and perindopril in stroke-prone spontaneously hypertensive rats

1 reference

12 December 2020

Effects of the new oral angiotensin converting enzyme inhibitor 2-[N-[(S)-1-ethoxycarbonyl-3-phenylpropyl]-L-alanyl]-(1S,3S,5S)-2- azabicyclo[3.3.0]octane-3-carboxylic acid (Hoe 498) in essential hypertension

1 reference

12 December 2020

[Effect of the angiotensin-converting enzyme inhibitor ramipril on proteinuria, blood pressure and kidney function in histologically confirmed glomerulonephritis with nephrotic syndrome]

1 reference

12 December 2020

Regulation of renal hemodynamics and glomerular filtration in patients with renovascular hypertension during converting enzyme inhibition with captopril

1 reference

12 December 2020

Acute effects of the new angiotensin converting enzyme inhibitor ramipril on hemodynamics and carotid sinus baroreflex activity in congestive heart failure.

1 reference

12 December 2020

Preliminary experiences with HOE 498, a novel long-acting converting enzyme inhibitor, in hypertensive patients

1 reference

12 December 2020

Mechanism of deterioration in renal function in patients with renovascular hypertension treated with enalapril

1 reference

12 December 2020

Pharmacokinetics and effects on the renin-angiotensin system of ramipril in elderly patients

1 reference

12 December 2020

Acute hemodynamic, hormonal and electrolyte effects of ramipril in severe congestive heart failure

1 reference

12 December 2020

Influence of renal function on the pharmacokinetics of ramipril (HOE 498)

1 reference

12 December 2020

Determination of 2-[N-[(S)-1-ethoxycarbonyl-3-phenylpropyl]-L-alanyl]-(1S,3S,5S)-2- azabicyclo[3.3.0]octane-3-carboxylic acid (Hoe 498) and its hydrolysis product in serum and urine

1 reference

12 December 2020

Effects of converting enzyme inhibitors: ramipril and enalapril on peptide action and sympathetic neurotransmission in the isolated heart

1 reference

12 December 2020

Short- and long-term effects of ramipril in hypertension.

1 reference

12 December 2020

Combined treatment of severe essential hypertension with the new angiotensin converting enzyme inhibitor ramipril

1 reference

12 December 2020

Inhibition of angiotensin converting enzyme by 2-[N-[(S)-1-carboxy-3-phenylpropyl]-L-alanyl]-(1S,3S,5S)-2-azabicyclo [3.3.0]octane-3-carboxylic acid (Hoe 498 diacid). Comparison with captopril and enalaprilat

1 reference

12 December 2020

Captopril: a preliminary review of its pharmacological properties and therapeutic efficacy

1 reference

12 December 2020

Influences of the chemical structure on the activity of new inhibitory compounds of the angiotensin-converting enzyme

1 reference

12 December 2020

Pharmacokinetics and pharmacodynamics of a novel orally active angiotensin converting enzyme inhibitor (HOE 498) in healthy subjects

1 reference

12 December 2020

Captopril. An update of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension and congestive heart failure

1 reference

12 December 2020

A double-blind study to compare the efficacy, tolerance and safety of two doses of the angiotensin converting enzyme inhibitor ramipril with placebo

1 reference

12 December 2020

Blood pressure response of nephrectomized subjects and patients with essential hypertension to ramipril: indirect evidence that inhibition of tissue angiotensin converting enzyme is important

1 reference

12 December 2020

Converting enzyme inhibition specifically prevents the development and induces regression of cardiac hypertrophy in rats

1 reference

12 December 2020

2-[N-[(S)-1-ethoxycarbonyl-3-phenylpropyl]-L-alanyl]-(1S,3S,5S)-2- azabicyclo[3.3.0]octane-3-carboxylic acid (Hoe 498): antihypertensive action and persistent inhibition of tissue converting enzyme activity in spontaneously hypertensive rats

1 reference

12 December 2020

First dose response and 24-hour antihypertensive efficacy of the new once-daily angiotensin converting enzyme inhibitor, ramipril

1 reference

12 December 2020

Physical performance during sustained converting enzyme inhibition with Hoe 498 in conscious dogs

1 reference

12 December 2020

Global and regional hemodynamic effects of ramipril in congestive heart failure

1 reference

12 December 2020

Comparative double-blind study of ramipril and captopril in mild to moderate essential hypertension

1 reference

12 December 2020

Dose-response relation of the angiotensin converting enzyme inhibitor ramipril in mild to moderate essential hypertension

1 reference

12 December 2020

Pharmacology of Converting Enzyme Inhibitors: New Aspects

1 reference

12 December 2020

Efficacy and safety of ramipril (HOE 498) in the treatment of hypertension: dose finding study.

1 reference

12 December 2020

Converting enzyme inhibitors and brain angiotensin

1 reference

12 December 2020

Angiotensin-converting enzyme inhibitors. Relationship between pharmacodynamics and pharmacokinetics

1 reference

12 December 2020

Acute and chronic effects of ramipril and captopril in congestive heart failure

1 reference

12 December 2020

Cardiovascular and antihypertensive activities of the novel non-sulfhydryl converting enzyme inhibitor 2-[N-[(S)-1-ethoxycarbonyl-3-phenylpropyl]-L-alanyl]-(1S,3S,5S)-2- azabicyclo[3.3.0]octane-3-carboxylic acid (Hoe 498)

1 reference

12 December 2020

Pharmacokinetics and pharmacodynamics of ramipril in renal failure

1 reference

12 December 2020

Enalapril, a nonsulfhydryl angiotensin-converting enzyme inhibitor.

1 reference

12 December 2020

Studies on the antihypertensive effect of single doses of the angiotensin converting enzyme inhibitor ramipril (HOE 498) in man

1 reference

12 December 2020

Angiotensin converting enzyme inhibitors enhance the antihypertensive efficacy of diuretics and blunt or prevent adverse metabolic effects

1 reference

12 December 2020

Cardiovascular and renal effects of ramipril

1 reference

12 December 2020

Influence of ramipril diacid on the peripheral vascular effects of angiotensin I.

1 reference

12 December 2020

Acute hemodynamic and hormonal effects of ramipril in chronic congestive heart failure and comparison with captopril

1 reference

12 December 2020

Efficacy, tolerance and hormonal effects of a new oral angiotensin converting enzyme inhibitor, ramipril (HOE 498), in mild to moderate primary hypertension

1 reference

12 December 2020

Antihypertensive treatment in spontaneously hypertensive rats with streptozotocin-induced diabetes mellitus

1 reference

12 December 2020

A dose-response study of HOE 498, a new non-sulphydryl converting enzyme inhibitor, on blood pressure, pulse rate and the renin-angiotensin-aldosterone system in normal man

1 reference

12 December 2020

Influence of the new angiotensin converting enzyme inhibitor ramipril on several models of acute inflammation and the adjuvant arthritis in the rat

1 reference

12 December 2020

The renin-angiotensin system and ramipril, a new converting enzyme inhibitor

1 reference

12 December 2020

Absence of interaction between ramipril, a new ACE-inhibitor, and phenprocoumon, an anticoagulant agent

1 reference

12 December 2020

Tolerance and pharmacodynamics of the angiotensin converting enzyme inhibitor 2-[N-[(S)-1-ethoxycarbonyl-3-phenylpropyl]-L-alanyl]-(1S,3S,5S)-2- azabicyclo[3.3.0]octane-3-carboxylic acid (Hoe 498) in healthy volunteers

1 reference

12 December 2020

An open multicenter study to assess the long-term efficacy, tolerance, and safety of the oral angiotensin converting enzyme inhibitor ramipril in patients with mild to moderate essential hypertension.

1 reference

12 December 2020

Inhibition of angiotensin converting enzyme: dependence of chloride

1 reference

12 December 2020

Pharmacokinetics and biotransformation of 2-[N-[(S)-1-ethoxycarbonyl-3-phenylpropyl]-L-alanyl]-(1S,3S, 5S)-2-azabicyclo [3.3.0]octane-3-carboxylic acid (Hoe 498) in rat, dog and man

1 reference

12 December 2020

Pharmacological properties of the new orally active angiotensin converting enzyme inhibitor 2-[N-[(S)-1-ethoxycarbonyl-3-phenylpropyl]-L-alanyl] -(1S,3S,5S)-2-azabicyclo[3.3.0]octane-3-carboxylic acid (Hoe 498)

1 reference

12 December 2020

Pharmacokinetics of ramipril in the elderly

1 reference

12 December 2020

Effects of the new angiotensin-converting enzyme inhibitor, ramipril, in patients with essential hypertension

1 reference

12 December 2020

A multi-centre comparative study between ramipril and enalapril in patients with mild to moderate essential hypertension

1 reference

12 December 2020

Effects of converting enzyme inhibition on split renal function in renovascular hypertension

1 reference

12 December 2020

Cough associated with angiotensin converting enzyme inhibition.

1 reference

12 December 2020

Kinetic properties of the angiotensin converting enzyme inhibitor ramiprilat

1 reference

12 December 2020

Influence of the Converting Enzyme Inhibitors Hoe 498, Enalapril and Captopril on Vascular Reactivity of Isolated Arterial Preparations

1 reference

12 December 2020

True versus immunoreactive angiotensin II in human plasma.

1 reference

12 December 2020

Enalapril. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension and congestive heart failure

1 reference

12 December 2020

2-[N-[(S)-1-ethoxycarbonyl-3-phenylpropyl]-L-alanyl]-(1S,3S,5S) -2-azabicyclo[3.3.0]octane-3-carboxylic acid (Hoe 498)--a new and highly effective angiotensin I converting enzyme inhibitor

1 reference

12 December 2020

Heart and vascular wall as targets for tissue converting enzyme inhibition

1 reference

12 December 2020

Converting enzyme inhibitor ramipril stimulates prostacyclin synthesis by isolated rat aorta: evidence for a kinin-dependent mechanism

1 reference

12 December 2020

Pharmacokinetic interaction study with ramipril and digoxin in healthy volunteers

1 reference

12 December 2020

Twenty-four hour changes in active and inactive renin after various oral doses of the converting enzyme inhibitor ramipril (HOE498) in normal man.

1 reference

12 December 2020

Vascular angiotensin conversion in humans.

1 reference

12 December 2020

Effects of sympathetic nerve stimulation are attenuated by the converting enzyme inhibitor Hoe 498 in isolated rabbit hearts

1 reference

12 December 2020

A radioimmunoassay for the angiotensin converting enzyme inhibitor ramipril and its active metabolite

1 reference

12 December 2020

Systemic and regional hemodynamic profile of five angiotensin I converting enzyme inhibitors in the spontaneously hypertensive rat.

1 reference

12 December 2020

Change in cough reflex after treatment with enalapril and ramipril

1 reference

12 December 2020

Pharmacological interferences with the renin-angiotensin system.

1 reference

12 December 2020

Disappearance of captopril-induced taste disturbance after substitution with angiotensin-converting-enzyme inhibitor HOE 498.

1 reference

12 December 2020

Use of nuclear magnetic resonance imaging to show regression of hypertrophy with ramipril treatment

1 reference

12 December 2020

The effect of an angiotensin converting enzyme inhibitor, ramipril, on bronchial responses to inhaled histamine and bradykinin in asthmatic subjects

1 reference

12 December 2020

Ramipril: review of pharmacology

1 reference

12 December 2020

Is tissue converting enzyme inhibition a determinant of the antihypertensive efficacy of converting enzyme inhibitors? Studies with the two different compounds, Hoe498 and MK421, in spontaneously hypertensive rats.

1 reference

12 December 2020

Converting enzyme inhibitor-induced changes of plasma angiotensinogen concentration in the rat

1 reference

12 December 2020

10.2165/00003495-199039010-00009

Identifiers

DOI

1 reference

Dimensions Publication ID

24 August 2017

1014179943

0 references

1 reference